Press releases

February 05, 2020
Regulatory

Year-end report 2019 Bactiguard Holding AB

A strong development in fourth quarter earnings, combined with the licensing deal with Zimmer Biomet led to the highest full-year result in Bactiguard's history. The financial effects of both increased BIP sales and new license revenues clearly show that our growth strategy works.

February 04, 2020
Regulatory

Christian Kinch resigns as CEO of Bactiguard and is proposed as new Chairman of the Board. Cecilia Edström appointed new CEO.

Christian Kinch today announced to the Board that he will resign as CEO of Bactiguard Holding AB (publ) after close to 16 years. The Board has appointed CFO and Deputy CEO Cecilia Edström as new CEO of Bactiguard and Stefan Grass (CMO) as Deputy CEO. Until a permanent CFO has been recruited, Financial manager Lina Arverud will hold the position as acting CFO.

Prior to the Board's decision, the Nomination Committee held an extraordinary meeting and decided to propose that Christian Kinch is elected new Chairman of the Board at the Annual General Meeting on April 28, 2020. The current Chairman of the Board Jan Ståhlberg has announced that he will be available for re-election as a Board member. The Nomination Committee proposes Jan Ståhlberg as Deputy Chairman of the Board.

February 04, 2020
Regulatory

Bactiguard makes its first acquisition by acquiring Vigilenz

Bactiguard deepens the partnership that was initiated in 2015 by acquiring Vigilenz Medical Devices and Vigilenz Medical Supplies (together Vigilenz) in Malaysia. The acquisition strengthens Bactiguard’s position in infection control and wound management, as well as innovation and product development capability and capacity. The consideration consists of a cash payment of USD 4.5 million payable at closing and, subject to approval by the annual general meeting of shareholders (AGM), 241 512 new class B-shares in Bactiguard, equivalent to a value of USD 2 million.

January 28, 2020

Invitation to presentation of Bactiguard’s year end report for 2019 on February 5, 2020

Bactiguard Holding AB (publ) publishes the year end report for 2019 on Wednesday, February 5, 2020 at 8:00 CET.

December 27, 2019
Regulatory

New major order from China

Bactiguard has received a new order from Well Lead Medical (Well Lead) in China. The order will be delivered promptly and generate revenues in the fourth quarter of approximately SEK 16.5 million.

November 07, 2019
Regulatory

Interim report for Q3 2019

The new license agreement with Zimmer Biomet contributed to that we delivered the strongest quarter to date for Bactiguard as a listed company. The partnership with one of the three largest orthopedic companies in the world confirms the strength of Bactiguard's technology in a global perspective and a new medical application for long-term use. The financial impact of the agreement also shows that our growth strategy works.

November 04, 2019

Invitation to presentation of Bactiguard’s interim report on November 7, 2019

Bactiguard Holding AB (publ) publishes the interim report for the third quarter on Thursday November 7, 2019 at 7:30 CET.

October 23, 2019
Regulatory

Nomination Committee appointed for the Annual General Meeting 2020

The members of the Nomination Committee for the Annual General Meeting of Bactiguard Holding AB (publ), to be held on Tuesday 28 April 2020 at the company’s headoffice in Botkyrka, have now been appoined.

September 29, 2019
Regulatory

New major order from China

Bactiguard has received a new order from Well Lead Medical (Well Lead) in China. The order will be delivered promptly and generate revenues in the third quarter of approximately SEK 4,8 million.

September 27, 2019
Regulatory

Bactiguard signs global license agreement with Zimmer Biomet

Bactiguard has entered into an exclusive, global license agreement for orthopedic trauma implants with Zimmer Biomet. The agreement includes an upfront license fee of USD 3 million payable at signing, additional contingent payments of USD 2 million, based on U.S. regulatory clearance and royalties on net sales following commercialization.

Pages